RxSight, Inc. granted inducement stock options for 571,286 shares and restricted stock units (RSUs) for 2,312,138 shares to Aziz Mottiwala, the company's new President and CEO, as part of his employment commencement on July 24, 2026. The stock options have an exercise price of $5.19 per share, matching the closing price on the grant date, with vesting spread over four years. The RSUs vest over three years with milestones at one, two, and three years. These grants are part of RxSight's 2026 Inducement Equity Incentive Plan and comply with Nasdaq rules. This move aims to incentivize Mottiwala's leadership as RxSight continues to innovate in adjustable intraocular lens technology for cataract surgery patients.
Toescoin, a memecoin on the Solana blockchain, announced talks with a major Japanese venture capital firm interested in investing up to $250,000 over time. This engagement aims to provide both funding and strategic support as Toescoin expands its pre...
A new patent application reveals a quantum AI project creating humanoid robots that can carry a person's 'digital DNA' to live alongside humans for centuries. This technology, part of a federally registered clinical trial, allows families to preserve...
TRX price remains stable near $0.33, supported by Tron Inc.'s ongoing treasury purchases and robust USDT transaction volume on the TRON network. Despite some weakening momentum indicators, buyers defend key support levels within an ascending channel....
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging the company may have provided misleading business information to investors in its stock-based mutual funds. Investors who purchased Pu...
Storj Labs filed for Chapter 11 bankruptcy to address old debts that it cannot resolve through growth. Despite the filing, the Storj network and STORJ tokens continue to operate normally. The company plans to offer token holders equity in the reorgan...
